Complex drugs have emerged in the COPD market, preannouncing keen competition

Following the hypertension • Diabetes treatment market, complex drugs have emerged in the COPD (Chronic Obstructive Pulmonary Disease) market, preannouncing keen competition.

As of this month 26, Novartis succeeded in receiving sales approval of 'Ultibro Breezhaler' which is a complex drug for the treatment of COPD, and composed of LABA formulation 'Onbrez Breezhaler' (ingredient Indacaterol) ...